Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAKURABONSAI open-label satralizumab study in NMOSD (AQP4+)
jRCT2021220014Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label trial of satralizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 cohorts), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Proportion of relapse-free patients, Annualized relapse rate (ARR) and 11 more. Started Jul 2022; status: completed.
02
Drugs
satralizumab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on jRCT2021220014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021220014.